Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23913875 | 0.68 | SCN10A (0.44) | NPC1LMNATP53RAB9ASMN1; SMN2 | |
| SCHEMBL12689681 | 0.68 | DGAT1 (0.38) | — | |
| SCHEMBL15935280 | 0.68 | LMNA (0.31) | LMNA | |
| SCHEMBL21025312 | 0.68 | TRPV1 (0.31) | — | |
| SCHEMBL21672141 | 0.67 | — | — | |
| SCHEMBL4548645 | 0.67 | TDO2 (0.33) | — | |
| SCHEMBL25449344 | 0.67 | FGFR1 (0.44) | — | |
| SCHEMBL8272414 | 0.67 | CCR1 (0.40) | LMNATP53SMN1; SMN2 | |
| SCHEMBL14327674 | 0.66 | CCR1 (0.52) | NPC1LMNATP53RAB9ASMN1; SMN2 | |
| SCHEMBL2705713 | 0.66 | LMNA (0.34) | LMNARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200039998-A1 | AMINE-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS AND METHODS OF USE THEREOF | Epizyme, Inc. | 2020-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200039998-A1 | AMINE-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS AND METHODS OF USE THEREOF | HNMT, BHMT, EHMT2 | NPC1 1623/4885LMNA 3404/4885TP53 1572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.